News
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...
1hon MSNOpinion
Voices: Yes, Mounjaro is set to treble in price – but don’t abandon weight-loss jabs until you read this
COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...
16h
Money Talks News on MSNWegovy Fallout: How Novo’s Exit Hits Your Wallet and Waistline
Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...
BRITAIN has gone fat jab crazy — with sales of Wegovy soaring by more than 2,000 per cent in the past month. Dieters are ...
Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...
BDCDA alerts traders in Karnataka on Novo Nordisk insulins & semiglutide injections’ pilferage in transit: Nandita ...
Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...
American tennis legend Serena Williams revealed taking the help of GLP-1 drugs to attain an ideal figure after struggling to ...
23h
Zacks Investment Research on MSNIs Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results